This site is intended for patients who have been prescribed Remicade (infliximab). If you are a Healthcare Professional then please visit the HCP site, or if you are a member of the public please visit our public site. This site is not a substitute for the Patient Information Leaflet (PIL). The information provided is general education information and does not take place of professional medical advice.


External link

The link you have selected is not under the review or control of MSD and, as such, the company does not endorse the content, its accuracy, or any practices or standards contained within it.

Please confirm you wish to follow this link.


References

  1. Kanai T et al. Korean J Intern Med 2014; 29(4): 409-15
  2. Olendzki BC et al. Nutr J 2014; 13(5): 1-7.
  3. Brown AC et al. Expert Rev. Gastroenterol. Hepatol 2011; 5(3): 411-25
  4. Pituch-Zdanowksa A et al. Prz Gastroenterol 2015; 10(3): 135-41.
  5. Oliviero F et al. Swiss Med Wkly 2015; 145: w14190.
  6. Clinton CM et al. Arthritis 2015; 2015: Article ID 708152.
  7. Narula N, Fedorak RN. Can J Gastroenterol 2008; 22 (5): 497-504
  8. Bilski J et al. BioMed Res Int 2014; Volume 2014 (Article ID 429031): 1-14.
  9. Benatti FB, Pedersen BK. Nat Rev Rheumatol 2015; 11: 86-97
  10. Nolte K et al. S Afr Fam Pract 2013; 55: 345-9
  11. Metsios GA et al. Expert Rev Clin Immunol 2015 [Epub ahead of print]
  12. Brophy S et al. Semin Arthritis Rheum 2013; 42: 619-26

Contact

For further information about Remicade (infliximab) please contact our Medical Information Department at:

Medical Information Department

Merck Sharp & Dohme Ltd.

Hertford Road

Hoddesdon

Hertfordshire

EN11 9BU

Tel: 01992 467272

E-mail: medicalinformationuk@merck.com